富含血小板血浆在骨组织工程中的应用研究

《富含血小板血浆在骨组织工程中的应用研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、北京协和医学院;中国医学科学院博士学位论文富含血小板血浆在骨组织工程中的应用研究姓名：雷华申请学位级别：博士专业：外科学（整形外科）指导教师：归来;张志勇20090131Applicationresearchonplatelet-richplasma。boneAODliCationresearclll0nplatelet-riclllplasmaInDonetissueengineeringAbstractObjectives：1．Conventionalstaticseedingmethodisnotefficientinestablishing3Dcell／scaffoldcom

2、posites，SOfibrinogenandotherhydrogelsareusedtoincreaseseedingefficiency．Platelet-richplasma(PRP)isderivedfromautologouswholebloodandrichinfibrinogenandplateletswhichreleasemultipleactivefactorsinresponsetothrombin．Therefore，wethinkusingplatelet-richplasma(PRP)asseedingintermediuminsteadoffibrin

3、ogenandotherhydrogelscanimprovecurrentstaticseedingtechnology．2．InPRPclinicalorresearchstudies，theanticoagulantapplicationdoesnotdrawenoughattentionsthoughanticoagulantsmightinfluencethequalityandthenbiologicaleffectofPRP．Thisstudyconductedacomparativestudytoinvestigatetheeffectoftheanticoagula

4、ntsonPRPqualitywishingtoclarifytheappropriateanticoagulantusedinPRPproduction．Methods：Totestourhypothesis，thisstudyevaluatedseedingefficiency，proliferationanddifferentiationofBMSCsseededintoPLGAporousscaffoldsviaPRP，autologousfibrinogen，andDMEMrespectively．Additionally，BMSCs／PLGAconstructsestab

5、lishedbyabovethreeintermediumswereimplantedingoatcalvarialdefectstoevaluatethecapabilityofPRPinenhancingboneregenerationbyradiologicalandhistologicalassay．2．Themicrostructurechangeofplateletscollectedviaheparin，citrate，acidcitratedextrose(ACD)andcitrate--theophylline-adenosine-dipyridamole(CTAD

6、)wasobservedbyTEMfollowingtimecourse．TheextentofspontaneousactivationofplateletsinfourgroupsWasdetectedbymeasuringsP-selectininplasma．TheTGF卡1releaseamountofactivatedPRPoffourgroupsWasmeasuredandthebiologicaleffectofPRPoncellproliferationwasalsostudied．Results：1．PI强notonlycouldincreaseBMSCsseed

7、ingefficiencylikefibrinogen，butalsocouldsignificantlystimulateBMSCsproliferationwithoutinhibitionBMSCsdifferentiationinvitroandobviouslyenhanceboneregenerationinvivocomparedwithDMEMandfibrinogen．2．CTADissuperiortOotheranticoagulan